A routine electrocardiogram, the inexpensive test that records the electrical activity of the heart through 10 electrodes placed on the skin, has long been one of medicine's most common and most underutilized tools. A trained cardiologist reading an ECG can identify certain arrhythmias and ischemic patterns, but significant structural heart disease, including early-stage heart failure, valve disease, and dangerous thickening of the heart muscle, can be entirely invisible on a standard ECG review.
That changed on June 23, 2026, when the U.S. Food and Drug Administration cleared EchoNext, developed by Pathway Labs and researchers at NewYork-Presbyterian and Columbia University Irving Medical Center. The clearance covers six separate cardiac conditions detectable from a standard 12-lead ECG, making EchoNext the world's first FDA-cleared AI tool to screen for multiple forms of structural heart disease from a test already performed in millions of clinical encounters every year.
Why This Matters
Heart disease kills more Americans than any other cause. Unlike cancer, for which routine mammography and colonoscopy have become standard parts of preventive care, there has been no equivalent early-detection screening for most forms of cardiovascular disease. An echocardiogram can identify structural heart disease with high accuracy, but it requires specialized ultrasound equipment, a trained technician, and costs significantly more than a routine ECG. The result is that structural heart disease is often diagnosed only after patients develop symptoms, by which point the disease may have progressed to a stage where treatment options are narrower.
"While we have mammograms and colonoscopies for cancer, we have never had an equivalent form of early detection for the most common cause of death in the world," said Dr. Pierre Elias, founder and CEO of Pathway Labs, medical director for artificial intelligence at NewYork-Presbyterian, and assistant professor of medicine and biomedical informatics at Columbia University. "Through EchoNext, we are able to detect high-risk conditions that the human eye can't and may otherwise be missed."
What We Know So Far
EchoNext was trained on more than 700,000 paired ECGs and echocardiograms collected across the NewYork-Presbyterian health system and subsequently validated across more than 20 hospitals and 500,000 patients in the United States and Canada. The tool is designed to identify signals in ECG waveforms that are imperceptible to the human eye but correlate with the presence of structural cardiac abnormalities that would be confirmed by echocardiography.
The six conditions EchoNext is cleared to flag are: left-sided heart failure, right-sided heart failure, valve disease, severe cardiac hypertrophy consistent with infiltrative cardiomyopathy, pulmonary hypertension, and cardiomyopathy. All of these conditions often produce no symptoms in their early stages, and all carry significantly better treatment outcomes when identified before symptoms develop.
In a head-to-head comparison with 13 cardiologists evaluating 3,200 ECGs, EchoNext correctly identified 77 percent of structural heart problems, while cardiologists making diagnoses based on the same ECG data achieved 64 percent accuracy. The tool also outperformed cardiologists who had access to AI assistance.
The day before the FDA clearance was announced, Nature Medicine published the first peer-reviewed case in which EchoNext detected undiagnosed heart failure in a 45-year-old man who had come to an emergency department for an unrelated reason. The AI flagged the ECG for follow-up echocardiography. That echocardiogram revealed an ejection fraction of approximately 10 percent, profoundly impaired heart function, along with a leaking mitral valve and a rare genetic disorder associated with sudden death. The patient ultimately received a heart transplant. Pathway Labs described this as the first heart transplant attributable to AI-based disease detection and the first peer-reviewed case of its kind.
Where the Impact Is Highest
The communities with the highest potential benefit from EchoNext are those where cardiology specialists are geographically scarce or access to echocardiography is limited. Rural hospitals and community health centers where ECGs are routinely performed but echocardiography requires a referral and a wait, sometimes weeks or months long, would gain the most from a screening tool that helps clinicians identify which patients actually need the more expensive and time-consuming study.
Within major U.S. cities, emergency departments and primary care practices in under-resourced neighborhoods that see high rates of cardiovascular disease but limited access to cardiologists could use EchoNext to triage patients more accurately. Through its partnership with OpenEvidence, a clinical decision platform used regularly by more than half of U.S. clinicians according to the company, EchoNext is designed to be available wherever an ECG is performed, not just at major academic medical centers.
What Doctors and Experts Say
Travis Zack, chief medical officer of OpenEvidence, framed the access dimension directly: "FDA-approved AI shouldn't sit siloed in the ivory tower while patients wait years for it to reach them. Putting EchoNext on OpenEvidence means a breakthrough in heart disease detection is available everywhere care happens, from major hospitals to community practices."
The tool is not intended to replace echocardiography or cardiologist judgment. Instead, it acts as a screening layer that identifies which patients among the millions who receive routine ECGs should go on to receive an echocardiogram for definitive evaluation. That triage function is where the clinical and economic value lies, narrowing the gap between widespread ECG availability and more selective echocardiography access.
What the Evidence Shows and What It Does Not
EchoNext was trained on 700,000 ECG-echocardiogram pairs and validated across 20 hospitals and 500,000 patients, an unusually large validation dataset for a cardiac AI tool. In a head-to-head comparison with 13 cardiologists on 3,200 ECGs, it outperformed cardiologist diagnosis with and without AI assistance. FDA clearance through the 510(k) pathway, which applies here, indicates that the FDA found the device to be substantially equivalent to a legally marketed predicate device in terms of intended use and technological characteristics.
FDA clearance is not the same as FDA approval, and it does not mean the tool is infallible. The published validation data covers structural heart disease detection broadly; performance on rarer conditions like infiltrative cardiomyopathy in community settings outside academic health systems remains to be established at scale. The system flags patients who should receive follow-up echocardiography; it does not make a definitive diagnosis. Readers should know that EchoNext is a screening tool that works within a clinical workflow, not a standalone consumer product.
Who Faces the Greatest Risk Without This Tool
Adults with undiagnosed structural heart disease who are not experiencing symptoms are the primary target population. This includes people who have had one or more ECGs performed in primary care, emergency, or preoperative settings where an elevated signal for structural disease may have been missed by standard clinical review. People over 50, those with a family history of cardiomyopathy or valve disease, and those with conditions associated with heart disease, including hypertension, diabetes, and chronic kidney disease stand to benefit most from a tool that catches disease earlier.
Symptoms and Warning Signs to Watch For
Structural heart disease, when asymptomatic, produces no reliable warning signs. This is precisely why an AI-assisted screening approach has clinical value. When symptoms do emerge, they can include unexplained shortness of breath with activity, leg swelling, fatigue that limits daily function, palpitations, episodes of dizziness or near-fainting, and in some cases sudden cardiac arrest without prior warning, particularly with infiltrative cardiomyopathies. These symptoms warrant prompt medical evaluation. A clinician who knows that EchoNext has flagged a structural abnormality on a prior ECG would initiate that evaluation much sooner.
What You Can Do Now
Patients who have had an ECG performed in the past year, particularly during an emergency visit, preoperative evaluation, or routine physical, can ask their physician whether the ECG was reviewed specifically for signs of structural heart disease and whether an AI-assisted second review was used. Patients with a family history of heart failure, valve disease, or cardiomyopathy who have not had a recent echocardiogram can ask whether their next ECG could be analyzed through a tool like EchoNext.
Clinicians interested in EchoNext can access information through Pathway Labs and through the OpenEvidence platform. The tool is designed for use by any clinician performing or reviewing ECGs, not exclusively cardiologists.
Cost and Access: What Patients Should Know
A standard 12-lead ECG costs between $50 and $200 depending on the clinical setting and insurance. Adding an AI-assisted reading layer does not substantially change the patient-facing cost of the test. Whether insurance payers will reimburse an additional AI-reading code for EchoNext specifically is subject to evolving payer policies for AI-assisted diagnostics. The downstream echocardiogram triggered by a positive EchoNext screen carries its own cost, typically $1,000 to $3,000, but that cost is offset when it replaces an emergency presentation or a delayed diagnosis of advanced disease.
What Happens Next
Pathway Labs is expanding EchoNext's availability through the OpenEvidence partnership and plans to continue publishing clinical outcomes data as the tool enters broader use. Additional validation studies in more diverse community populations are expected to follow. Nature Medicine's publication of the heart transplant case is likely to drive further academic interest in reporting clinical outcomes attributable to AI-assisted ECG screening. MedicalDaily will track EchoNext's clinical and regulatory developments as they occur.
The Bottom Line
EchoNext's FDA clearance represents a meaningful advance in cardiovascular preventive medicine: an AI tool that can detect hidden, dangerous structural heart disease from a routine test that is already performed millions of times a year in U.S. clinical settings. The tool does not replace cardiologist judgment or echocardiography, but it identifies who needs the follow-up that has always been the hard part. For a disease category that kills more Americans than anything else and still lacks a mammogram equivalent, that is a genuinely important step.
